Sernova tech could power next-gen cell therapies for AstraZeneca

4 May 2023
lab_test_biotech_research_2021_big

Canada’s Sernova (TSX: SVA) has entered into a pre-clinical research collaboration with AstraZeneca (LSE: AZN), centered around its Cell Pouch System.

Sernova is focused on developing novel cell therapeutics, with the goal of creating a functional cure for insulin-dependent diabetics.

The Cell Pouch System is a novel implant which naturally vascularize with surrounding tissues, creating an environment for the production and release of absent or under-expressed hormones and proteins.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology